Clinical trials: MDS
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.
- Trial name
- NCT03225287
- Testing
- Zilucoplan (RA101495)
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 19 people
- Sponsor
- Ra Pharmaceuticals, Inc.
Myelodysplastic Syndrome
Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients
Allogeneic blood stem cell transplant remains the only potential curative treatment for myelodysplastic syndromes (MDS) to date.
- Trial name
- NCT01333449
- Testing
- Decitabine
- Where
- Singapore
- Volunteers
- 6 people
- Sponsor
- Singapore General Hospital
Lower-risk Myelodysplastic Syndromes
Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan
The purpose of this study is to describe the treatment patterns, clinical outcomes, healthcare resource utilization (HCRU) and medical costs of lower-risk myelodysplastic syndromes patients in Japan.
- Trial name
- NCT06298643
- Testing
- Red blood cell transfusion
- Where
- Japan
- Volunteers
- 177 people
- Sponsor
- Bristol-Myers Squibb
Preleukemia, Myeloproliferative Disorders
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
This is a clinical research study designed to evaluate whether the administration of a vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag peptide) mixed with G-CSF (a drug intended to…
- Conditions
- Preleukemia, Myeloproliferative Disorders, Lymphoma, Myeloma
- Trial name
- NCT00943293
- Testing
- Fludarabine, Melphalan, Campath
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Hodgkin Lymphoma, Lymphocytic Leukemia
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
Background: Allogeneic blood and marrow stem cell transplantation (BMT) plays an important role in the curative treatment of a number of pediatric malignancies.
- Conditions
- Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00013533
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloid, Acute
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment naïve acute myeloid leukemia (AML) who are…
- Trial name
- NCT04241549
- Testing
- Cusatuzumab, Azacitidine
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- OncoVerity, Inc.
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Myelodysplastic Syndrome
Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
This is a Phase I trial for patients with intermediate or high risk myelodysplastic syndrome (MDS). The study agent, clofarabine, is produced by Genzyme Pharmaceuticals.
- Trial name
- NCT01003678
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Roswell Park Cancer Institute
Hemoglobinuria, Paroxysmal
Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
- Trial name
- NCT00122304
- Testing
- eculizumab
- Where
- 48 sites in United States, Australia and 11 more
- Volunteers
- 85 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia (MDS) undergoing cord blood…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes, Other Acute Leukemias
- Trial name
- NCT03483324
- Testing
- Unmanipulated Umbilical Cord Blood (UCB), AB-110
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Angiocrine Bioscience
Leukemia, Myelodysplastic Syndromes
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
RATIONALE: Monoclonal antibodies can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00618696
- Testing
- anti-CD45 monoclonal antibody AHN-12, yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell…
- Conditions
- Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06928662
- Testing
- Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Neoplasms
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
The primary objectives of Phase 1 Dose Escalation/Part 1 Expansion are: To assess the safety and tolerability of treatment with enasidenib administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle…
- Trial name
- NCT01915498
- Testing
- Enasidenib
- Where
- 24 sites in United States, France
- Volunteers
- 345 people
- Sponsor
- Celgene
Myelodysplastic Syndromes, Acute Leukemia
Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia
RATIONALE: Giving chemotherapy and total marrow and lymphoid irradiation before allogeneic hematopoietic cell transplant helps stop the growth of leukemia cells.
- Trial name
- NCT03408210
- Testing
- total body irradiation, total marrow and lymphoid irradiation
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.
- Conditions
- Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute, Myeloproliferative-Myelodysplastic Diseases
- Trial name
- NCT00619879
- Testing
- Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients, Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies, Hematopoietic Progenitor Cell Transplantation (HPCT)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Myelodysplastic Syndromes
A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept
The purpose of this study is to understand the treatment use of luspatercept in adults diagnosed with lower-risk myelodysplastic syndromes
- Trial name
- NCT07075406
- Testing
- Luspatercept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid…
- Conditions
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome
- Trial name
- NCT00801489
- Testing
- Cytarabine, Decitabine, Filgrastim-sndz
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- M.D. Anderson Cancer Center
MDS, Leukemias
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
The purpose of this study is to see if giving high dose chemotherapy and total body irradiation before and repeating high dose chemotherapy after a bone marrow transplant could reduce the incidence of graft rejection and disease…
- Conditions
- MDS, Leukemias, Lymphomas
- Trial name
- NCT00796562
- Testing
- Busulfan, Cyclophosphamide, Total body irradiation
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with relapsed or refractory solid tumors or myelodysplastic syndromes.
- Conditions
- Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia
- Trial name
- NCT00104962
- Testing
- lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.